295 reports of suspected side effects of implants in 2023 In 2023, 295 individuals reported one or more suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI).
RIVM identifies three major challenges for public health and healthcare in period to 2050 The Dutch public health and healthcare will face three crucial challenges in the period to 2050. This is according to RIVM’s preview of the Dutch Public Health Foresight Study 2024.
Participation rates in cancer population screening programmes continue to decline The number of participants in the population screening programmes for breast cancer, cervical cancer and colorectal cancer continues to decline. This decline has been going on for years, reaching its lowest point in 2020.
Metabolic disorder ALD added to newborn blood spot screening Since 1 October, the metabolic disorder adrenoleukodystrophy (ALD) has been added to the Dutch newborn blood spot screening. From now on, the blood of newborn boys will also be tested for this disorder. ALD in boys can be treated if it is detected in time.
MEBI: 193 reports of suspected side effects of implants in 2022 In 2022, 193 individuals reported suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI). Most reports received concerned breast implants, copper IUDs and wrinkle fillers. This is highlighted in MEBI’s annual report.
From 1 October 2023, heel prick test also screens for metabolic disorder ALD From 1 October 2023, the blood of newborn babies will also be tested for the metabolic disorder adrenoleukodystrophy (ALD). This is done with the heel prick screening test.
NIPT available as standard option for all pregnant women from 1 April From 1 April 2023, the Non-Invasive Prenatal Test (NIPT) will be available to all pregnant women. They do not have to take part in a scientific study for this.
Higher alert level for Ebola There is an Ebola outbreak in several regions of Uganda that are also frequented by tourists. RIVM therefore asks medical professionals to be alert to symptoms that could indicate Ebola among people who have travelled to Uganda, and to request diagnostics to rule out or confirm Ebola.
Cancer screening programmes now more accessible to transgender and intersex persons Since October 2022, is it has become easier for transgender and intersex persons to take part in cervical cancer screening and breast cancer screening. Transgender and intersex persons with a uterus and/or breast tissue can register with Bevolkingsonderzoek Nederland.
New risk limits for PFAS in surface water The National Institute for Public Health and the Environment (RIVM) has derived new risk limits for PFAS in surface water. The guiding principle for these limits is that people should be able to consume fish sourced from surface water throughout their lives without ingesting excessive levels of PFAS.